Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...
POLICY PAPERS
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...
Blog Post
November 15, 2022
Congress has excellent legislation on the docket that would protect American citizens, yield huge returns, and create a safer, healthier world. We encourage the US Congress to urgently finance and authorize the PASTEUR Act, leveraging American ingenuity to boost our shared health future.
Blog Post
November 07, 2022
What’s the latest in international economic development research? Last weekend was the North East Universities Development Consortium annual conference, often called NEUDC. With more than 135 papers presented (and almost all of them available for download), it’s a great way to see recent trends in t...
Blog Post
October 04, 2022
Most R&D money flows from the private sector, which aims to maximize returns on investment. As a result, health R&D largely skews towards rich countries’ priorities and health system technical capacities, leaving significant gaps in diseases that primarily affect poor and marginalized populations.
POLICY PAPERS
October 04, 2022
In this paper, we report the results of a horizon-scanning exercise to source opportunities for global health R&D investment—that is, high-value potential biomedical innovations which are currently underfunded but which could be transformative for health, quality of life, and health security in LMIC...
Blog Post
September 26, 2022
Antimicrobial resistance is a major global problem. Today, drug resistant infections kill an estimated 1.27 million people per year, and low- and middle-income countries bear the brunt of AMR-related deaths and illness. Changing how we buy antimicrobials can help solve the problem.